Blog

Johnson & Johnson pens Alzheimer’s gene therapy pact – FierceBiotech


FierceBiotech

Johnson & Johnson pens Alzheimer's gene therapy pact
FierceBiotech
The workaround being pursued by J&J is underpinned by AAV research performed by Jim Wilson, M.D., Ph.D. and others at the university's gene therapy program. Wilson and his collaborators have been working to improve AAVs for more than two decades

2018-01-05 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.